| Trial ID: | L4135 |
| Source ID: | NCT00824616
|
| Associated Drug: |
Mk-0941
|
| Title: |
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00824616/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK-0941|DRUG: Placebo|DRUG: Insulin
|
| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Level, HbA1c level is a blood test measurement of the amount (percent) of hemoglobin that is glycated (or has glucose on it). HbA1c level is related to the average blood glucose concentration over the previous 2-3 months, with a higher HbA1c level indicating a higher amount of average plasma glucose. A negative number for change from baseline in HbA1c level means a reduction in HbA1c level and indicates better control of average plasma glucose levels., Baseline (Day 1) and End of Treatment (Week 20)|Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic), Hypoglycemic episodes - with or without symptoms - are defined as a fingerstick glucose measurement of ≤70 mg/dL (3.9 mmol/L). Excludes data after initiation of glycemic rescue therapy., From first dose of study drug (Week 0) to last dose of study drug (Week 20) |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
68
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-01
|
| Completion Date: |
2010-05
|
| Results First Posted: |
2012-08-21
|
| Last Update Posted: |
2015-07-28
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00824616
|
